Corrigendum to PCSK9 inhibition with alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: The ODYSSEY KIDS study Volume 14, Issue 3, May-June 2020, Pages 322-330.e5

J Clin Lipidol. 2020 Sep-Oct;14(5):741. doi: 10.1016/j.jacl.2020.08.011.

Authors

Stephen Daniels¹, Sonia Caprio², Umesh Chaudhari³, Garen Manvelian³, Marie T Baccara-Dinet⁴, Aurelie Brunet⁴, Michel Scemama⁵, Virginie Loizeau⁵, Eric Bruckert⁶

Affiliations

¹ University of Colorado School of Medicine, Aurora, CO, USA. Electronic address: Stephen.Daniels@childrenscolorado.org.
² Yale Pediatric Endocrinology, New Haven, CT, USA.
³ Regeneron Pharmaceuticals Inc, Tarrytown, NY, USA.
⁴ Sanofi, Montpellier, France.
⁵ Sanofi, Chilly-Mazarin, France.
⁶ Hôpital Pitié Salpêtrière, Paris, France; Institute of Cardiometabolism and Nutrition, Paris, France.

PMID: 33138961
DOI: 10.1016/j.jacl.2020.08.011

No abstract available

Publication types

Published Erratum